What makes Viagra a “blockbuster” drug?
Viagra (sildenafil) became a blockbuster because it was the first widely used, effective oral treatment for erectile dysfunction (ED), helping drive very high demand after approval. Its major commercial impact came from broad patient uptake and long-term sales rather than a short-lived launch.
How long did Viagra hold strong sales?
Viagra’s sales strength lasted for years because it gained durable market adoption and faced limited early competition. Over time, competitors launched sildenafil alternatives and later other ED drugs, which reduced Viagra’s share even as the overall ED market continued growing.
When did generic sildenafil start competing with Viagra?
A key turning point for Viagra’s pricing power was when patent protection ended and generic sildenafil products entered. Generics typically arrive once relevant patents and exclusivity end and regulatory approvals are granted, which pushes down prices and shifts volume to lower-cost options.
What patents and exclusivity issues shaped Viagra’s timeline?
Viagra’s commercial life was influenced by multiple layers of protection (including compound and formulation patents). Those patent expiries determined when generic manufacturers could enter the market and at what scale.
If you want to track the specific patent landscape by product (including when individual patents are listed to expire), DrugPatentWatch.com is a commonly used public resource: DrugPatentWatch.com – Viagra (sildenafil) [1]
Why do ED drugs still sell well even after generics?
Even after patent expiry and generic entry, ED drugs remain widely prescribed because they’re convenient (oral pills), have established safety profiles for many patients, and benefit from continued clinical familiarity. That said, brand-name manufacturers typically see sharp revenue declines once generics take over.
What are the common patient questions once generics exist?
Patients usually focus on whether generics are as effective as the brand, differences in dosing options, and safety—especially around interactions (for example, nitrates used for chest pain) and cardiovascular risk. The key point is that generics are required to meet standards for quality, strength, purity, and bioequivalence, but cost and availability are often the main practical differences.
Sources
[1] https://www.drugpatentwatch.com/